AIM+/+ and AIM-/- mice exhibit comparable liver damage in response to CCl4.
(A) AST and ALT at 0, 4, 8, 12 wk after administration of CCl4 (1.6 g/kg body weight, twice injection per week for 12 weeks) in AIM+/+ mice (+/+) and AIM-/- mice (−/−). n = 3 for each. Error bar: SEM, *: p<0.05 vs. before CCl4 administration (0 w). (B, C) mRNA levels of TNFα, IL-1β, IL-6 and MCP-1 (B); or CD11c, CD163, Arg-1 and MR (C) were assessed by QPCR using RNA isolated from liver after administration of CCl4 for 3 weeks. n = 3 for each. Error bar: SEM, *: p<0.05. (D) Sirius-red staining of the liver specimens after administration of CCl4 for 12 weeks to AIM+/+ mice (+/+) and AIM-/- mice (−/−). Bar: 100 µm. Right graph shows the quantification of fibrotic area. (E) mRNA levels of TGFβ, αSMA, Col4a1 and CTGF were assessed by QPCR using RNA isolated from liver from mice after administration of CCl4 for 3 weeks. n = 3 for each. Error bar: SEM; *: p<0.05, ***: p<0.001. (F) Left: Serum AIM levels were measured by ELISA from wild-type mice after administration of CCl4. n = 6 for each. Error bar: SEM, *: p<0.05 vs. before CCl4 administration (0 w). Right: Serum IgM levels were measured by semi-quantitative immunoblotting using sera from AIM+/+ (+/+) mice and AIM-/- (−/−) after administration of CCl4. Purified mouse IgM clone (3F3) was used as standard. Quantification of signals from immunoblotting was performed by using ImageQuant TL software (GE Healthcare, Little Chalfont, UK). n = 6 for each. Error bar: SEM; *: p<0.05, ***: p<0.01, vs. before CCl4 administration (0 w) in AIM+/+ (+/+) mice; ###: p<0.001 vs. before CCl4 administration in AIM-/- mice.